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Open access undBackground and purpose: The purpose of this large multicentre prospective cohort study was to identify
which dose volume histogram parameters and pre-treatment factors are most important to predict phy-
sician-rated and patient-rated radiation-induced swallowing dysfunction (RISD) in order to develop pre-
dictive models for RISD after curative (chemo) radiotherapy ((CH) RT).
Material and methods: The study population consisted of 354 consecutive head and neck cancer patients
treated with (CH) RT. The primary endpoint was grade 2 or more swallowing dysfunction according to the
RTOG/EORTC late radiation morbidity scoring criteria at 6 months after (CH) RT. The secondary endpoints
were patient-rated swallowing complaints as assessed with the EORTC QLQ-H&N35 questionnaire. To
select the most predictive variables a multivariate logistic regression analysis with bootstrapping was
used.
Results: At 6 months after (CH) RT the bootstrapping procedure revealed that a model based on the mean
dose to the superior pharyngeal constrictor muscle (PCM) and mean dose to the supraglottic larynx was
most predictive.
For the secondary endpoints different predictive models were found: for problems with swallowing liq-
uids the most predictive factors were the mean dose to the supraglottic larynx and radiation technique
(3D-CRT versus IMRT). For problems with swallowing soft food the mean dose to the middle PCM, age
(18–65 versus >65 years), tumour site (naso/oropharynx versus other sites) and radiation technique
(3D-CRT versus IMRT) were the most predictive factors. For problems with swallowing solid food the
most predictive factors were the mean dose to the superior PCM, the mean dose to the supraglottic larynx
and age (18–65 versus >65 years). And for choking when swallowing the V60 of the oesophageal inlet
muscle and the mean dose to the supraglottic larynx were the most predictive factors.
Conclusions: Physician-rated and patient-rated RISD in head and neck cancer patients treated with (CH)
RT cannot be predicted with univariate relationships between the dose distribution in a single organ at
risk and an endpoint. Separate predictive models are needed for different endpoints and factors other
than dose volume histogram parameters are important as well.
 2011 Elsevier Ireland Ltd.Open access under the Elsevier OA license.
Radiotherapy and Oncology 105 (2012) 107–114Swallowing dysfunction after curative (chemo) radiotherapy
((CH) RT) in head and neck cancer (HNC) has a signiﬁcant impact
on health-related quality of life (HRQoL) [1–7]. As the incidence
of radiation-induced xerostomia is reduced by the use of new radi-
ation techniques, such as intensity-modulated radiotherapy (IMRT)
[8], the problem of swallowing dysfunction is becoming one of the
most relevant side effects of (CH) RT.diation Oncology, University
roningen, The Netherlands.
gendijk).
er the Elsevier OA license.Radiation-induced swallowing dysfunction (RISD) has been
associated with a variety of motility disorders, which most likely
result from mucosal swelling and ﬁbrosis of the multiple muscles
and other structures involved in swallowing [1,9–12]. Indeed, a
number of authors found signiﬁcant relationships between the
dose distributions in swallowing organs at risk (SWOARs) and
RISD, such as the dose to the pharyngeal constrictor muscles
(PCMs) and glottic and supraglottic regions [13–18]. However,
most of these studies only investigated univariate relationships be-
tween the dose distributions to potential SWOARs and different as-
pects of RISD and did not take into account other potential
108 Predictive modelling swallowing dysfunctionconfounding and/or independent prognostic factors, such as the
addition of concomitant chemotherapy to radiation, fractionation
schedules and the primary tumour site [19–22]. Data published
so far do not provide sufﬁcient information regarding which Dose
Volume Histogram (DVH) parameters of the SWOARs are most
important in predicting RISD and how they can be used for treat-
ment planning optimisation. To be able to test the value of ade-
quate numbers of potential prognostic factors, large prospective
cohort studies and sophisticated statistical methods are required
for the development of reliable predictive models.
Therefore, the purpose of this large prospective cohort study
was to identify the most important DVH-parameters and other
pre-treatment factors that determine physician-rated and pa-
tient-rated RISD in order to develop predictive models for RISD
after curative (CH) RT.Methods and materials
Patients
The study population of this prospective cohort study consisted
of 354 consecutive patients, treated from 1997 either in the VU
University Medical Center (VUMC), Amsterdam or in the University
Medical Center Groningen (UMCG), Groningen, The Netherlands.
Table 1 shows the demographic, tumour and treatment character-
istics of the study population. All patients were treated with cura-
tively intended conventional three-dimensional conformal RT
(3D-CRT) or intensity-modulated RT (IMRT) for HNC, either alone
or in combination with concomitant chemotherapy or cetuximab.Table 1
Patients characteristics.
Characteristics Number %
Sex
Male 261 74
Female 93 26
Age (years)
18–65 222 63
>65 132 37
Tumour classiﬁcationa
T0 16 5
T1 64 18
T2 151 43
T3 68 19
T4 55 15
Node classiﬁcationa
N0 200 57
N1 39 11
N2a 15 4
N2b 38 11
N2c 53 15
N3 9 2
Primary site
Larynx 164 47
Oropharynx 91 26
Oral cavity 19 5
Hypopharynx 18 5
Nasopharynx 14 4
Unknown primary 8 3
Other 40 11
Treatment modalities
Conventional radiotherapy 95 27
Accelerated radiotherapy 188 53
Chemoradiation 71 20
Radiation technique
3D-CRT 219 62
IMRT 135 38
Baseline swallowing dysfunction (RTOG)
Grade 0 304 86
Grade 1 50 14
a According to the UICC TNM-classiﬁcation, 7th edition, 2009.All patients were subjected to a standardised follow-up pro-
gramme which included prospective evaluation of toxicity and
HRQoL, prior to, during and at regular intervals after curative
(CH) RT. Acute and late toxicity were graded according to the
RTOG/EORTC Radiation Morbidity Scoring Criteria [23]. HRQoL
was assessed using the EORTC QLQ-C30 and the additional head
and neck cancer module (the EORTC QLQ-H&N35) [24–26].
Patients who previously underwent surgery, radiotherapy
and/or chemotherapy, who had prior malignancies, and/or distant
metastases were excluded. Patients with RTOG grade 2–4 swallow-
ing dysfunction at baseline were also excluded in order to ensure
that the observed swallowing dysfunction was induced by radia-
tion treatment itself and not by tumour extension. Patients with
recurrences at 6 months were also excluded.Endpoints
The primary endpoint was deﬁned as grade 2–4 swallowing
dysfunction according to the RTOG/EORTC Late Radiation Morbid-
ity Scoring Criteria as assessed 6 months after completion of (CH)
RT (SWALM6). This time point was chosen as swallowing dysfunc-
tion at 6 months after treatment turned out to be very predictive
for swallowing dysfunction at subsequent time points [20].
The secondary endpoints were moderate to severe patient-rated
swallowing complaints at 6 months after (CH) RT as assessed with
the EORTC QLQ-H&N35 questionnaire. For these endpoints, 4 ques-
tions related to swallowing were used, including questions 35
(‘‘Have you had problems swallowing liquids?’’), 36 (‘‘Have you
had problems swallowing soft food?’’), 37 (‘‘Have you had prob-
lems swallowing solid food?’’) and 38 (‘‘Have you choked when
swallowing?’’).Treatment
Until the end of 2007, the majority of patients were treated with
3D-CRT. Since 2008 patients were increasingly treated with IMRT.
Radiotherapy was delivered using megavoltage equipment (6 MV
linear accelerator). For all patients, a contrast-enhanced planning
CT scan was made in supine treatment position.
Patients with early glottic carcinoma were treated with a frac-
tion dose of 2 Gy (5 or 6 times/week) up to a total dose of 66 Gy.
These patients were irradiated at the primary site without elective
neck treatment. Patients treated with concomitant CHRT were irra-
diated with a conventional fractionation schedule (2 Gy per frac-
tion, 5 times per week up to 70 Gy in 7 weeks). In case of
primary radiotherapy of the more advanced tumours, which were
considered ineligible for CHRT, an accelerated schedule with con-
comitant boost technique was used, either or not combined with
cetuximab. These patients were treated with 6 fractions per week
with a second fraction on Friday afternoon with a minimum inter-
val of 6 h, up to a total dose of 70 Gy in 6 weeks.
In patients treated with 3D-CRT, no attempts were made to
spare the salivary glands. Most of these patients received bilateral
elective irradiation of the neck nodes to a total dose of 46 Gy and a
boost on the primary tumour and pathological lymph nodes to a
total dose of 70 Gy.
IMRT treatments attempted to spare the parotid glands without
compromising the dose to the target volumes. In general, 7-ﬁeld
equidistant, non-opposing beams were applied. All IMRT treat-
ments applied a simultaneous integrated boost (SIB). Most patients
received bilateral elective irradiation of the neck nodes to a total
dose of 54.25 Gy, in fractions of 1.55 Gy. The primary tumour
and pathological lymph nodes were treated to a total dose of
70 Gy, in 2 Gy fractions.
Chemotherapy was given concurrently with conventionally
fractionated radiotherapy and consisted of cisplatin 100 mg/m2
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(300–350 mg/m2 in 30 min intravenously) and 5-ﬂuorouracil
(5-FU) from day 1 to 4 by continuous infusion (600 mg/m2/
24 h), consisting of 3 courses given with an interval of 3 weeks
(in the UCMG).Contouring of organs at risk
The SWOARs were delineated by one radiation oncologist,
according to the guidelines for SWOARs potentially involved in
RISD as described by Christianen et al. [27] including the superior,
middle and inferior PCM, the cricopharyngeal muscle, the oesoph-
agus inlet muscle (EIM), the cervical oesophagus, the base of ton-
gue and the supraglottic and glottic larynx. The parotid and
submandibular salivary glands were delineated according to the
guidelines described by Van de Water et al. [28].Dose distribution calculations
Since different treatment planning systems were used in the
VUMC and the UMCG, all data (i.e., contours and dose distribu-
tions) were transferred to the VODCA software program (VODCA
Company: viewer version 4.2.2. and database version 4.1.1). This
system allows reconstruction of the original dose distributions in
all aforementioned potential OARs and the generation of DVHs. Fi-
nally, all DVH data (the mean dose and the V5 up and until the
V70) were merged with all other potential pre-treatment prognos-
tic factors for each individual patient into one database.Statistics
For the development of the predictive models for all endpoints,
a multivariate logistic regression analysis was used with an ex-
tended bootstrapping technique and forward variable selection as
described by El Naqa et al. [29]. In contrast to the methods de-
scribed by El Naqa et al. [29], we used the likelihood criterion, in-
stead of correlation measures. The average likelihood was
calculated over all test data sets for each combination of variables.
The model which gave the highest average likelihood was selected
as the most predictive model.
Based on a former analysis by Langendijk et al. [20], we divided
the variable primary tumour site into 2 groups, including orophar-
ynx and nasopharynx versus all other sites.
Before carrying out the regression analysis, a correlation matrix
was produced to check for high correlations between potential
prognostic factors, in particular between DVH-parameters. In case
of Pearson correlation coefﬁcientsP0.80 between candidate prog-
nostic factors, only one variable was selected and entered in the
model in order to avoid the problem of multicollinearity which
may negatively affect the generalizability of the model.
The multivariate logistic regression was performed with 2000
bootstraps for each analysis. For every model order, and every
prognostic factor, the average total likelihood of the predictions
was calculated. The set of factors with the highest average total
likelihood was selected for the deﬁnite predictive models for
SWALM6 and patient-rated swallowing dysfunction.
Adjusted Odds ratios (OR) and 95% conﬁdence intervals (95% CI)
were calculated for the selected variables in the models. For each
patient, predictions (i.e., NTCP values) were calculated using the
set of n prognostic variables (x), and the regression coefﬁcients
(b) according to the formula:
NTCP ¼ ð1þ esÞ1; in which
S ¼ b0 þ
Xn
i¼1
bi  xiCalculation of the NTCP values is also presented in nomograms
(see Appendices). The NTCP curves for the different categories are
depicted in ﬁgures.
Model performance was determined by calculating the area un-
der the curve (AUC) of the receiver operating characteristics.
Results
Variable reduction and dose distribution procedure
A very strong correlation was found between almost all DVH
parameters within each swallowing organ at risk (SWOAR) and
the mean dose of that SWOAR. Therefore, we included only the
mean doses of all SWOARs in the analysis, except for the oesopha-
gus inlet muscle (EIM). For that structure the correlation between
the mean dose and the V50 and the V60 was low, and therefore we
entered the mean dose as well as the V50 and V60 in the analyses.
In addition, the correlation between the mean dose in the ipsilat-
eral and contralateral parotid, and submandibular glands, was very
strong. Therefore, we used the mean dose in the ipsi- and contra-
lateral parotid gland as one single variable. The same procedure
was followed for the submandibular glands.Primary endpoint: physician-rated swallowing dysfunction 6 months
after (CH) RT (SWALM6)
In the univariate analysis, the mean dose to the superior pha-
ryngeal constrictor muscle (PCM), the middle PCM, the EIM, the
cervical oesophagus, the base of tongue, the supraglottic larynx,
the parotid glands, and the submandibular glands, as well as the
V50 of the EIM were signiﬁcantly associated with SWALM6 (Table
2). In addition, T-stage (T1–2 versus T3–4), N-stage (N0 versus N+),
tumour site (oropharynx/nasopharynx versus other sites), concom-
itant chemotherapy, bilateral neck irradiation and baseline swal-
lowing dysfunction (grade 0 versus grade 1) were also
signiﬁcantly associated with SWALM6.
The variables included as candidate prognostic factors in the
multivariate model are similar to those listed in Table 2. In the
multivariate logistic regression analysis, the average likelihood of
bootstrap prediction was optimal with a model consisting of two
variables, including the mean dose to the superior PCM and the
mean dose to the supraglottic larynx. Model performance was
good with an AUC of 0.80 (95% CI 0.75–0.85). The OR’s for each
of the 2 selected variables are shown in Table 3. The NTCP value
for the individual patient can be calculated using the formula:
NCTP ¼ ð1þ esÞ1; in which
S = 6.09 + (mean dose PCM superior  0.057) + (mean dose supra-
glottic larynx  0.037).
The NTCP-curves for the different categories are depicted in
Fig. 1. Alternatively the NTCP-value for each individual patient
can be determined using the nomogram for SWALM6 as depicted
in Appendix A.Secondary endpoints: patient rated swallowing dysfunction
The results of the univariate logistic regression analysis for the
four patient-rated endpoints are listed in Table 2.Problems with swallowing liquids
For problems with swallowing liquids, the model was most
optimal with two variables, including the mean dose to the supra-
glottic larynx and radiation technique (3D-CRT versus IMRT). The
AUC for this 2-factor model was 0.75 (95% CI 0.68–0.83). The
OR’s for each of the 2 selected variables are shown in Table 3.
Table 2
Results of the univariate analysis of the primary and secondary.
Variable Endpoints at 6 months after completion of radiotherapy
Grade 2–4 RTOG swallowing
dysfunction
Q35: Problems swallowing
liquids
Q36: Problems swallowing
soft food
Q37: Problems swallowing
solid foods
Q38: Choking when
swallowing
OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value
Mean dose superior PCM (Gy) 1.06 (1.04–1.08) <0.01 1.02 (1.00–1.04) 0.027 1.04 (1.02–1.06) <0.01 1.05 (1.03–1.07) <0.01 1.00 (0.98–1.02) ns
Mean dose middle PCM (Gy) 1.06 (1.04–1.09) <0.01 1.05 (1.02–1.07) <0.01 1.06 (1.03–1.09) <0.01 1.06 (1.03–1.09) <0.01 1.02 (0.99–1.05) ns
Mean dose inferior PCM (Gy) 1.01 (0.99–1.03) ns 1.04 (1.01–1.07) 0.013 1.02 (0.99–1.04) ns 1.02 (1.00–1.05) 0.047 1.07 (1.01–1.13) 0016
Mean dose cricopharyngeal muscle (Gy) 1.01 (0.99–1.02) ns 1.03 (1.00–1.05) 0.026 1.00 (0.99–1.02) ns 1.02 (0.99–1.04) ns 1.04 (1.00–1.07) 0033
Mean dose EIM (Gy) 1.03 (1.01–1.04) <0.01 1.01 (0.99–1.03) ns 1.01 (0.99–1.03) ns 1.03 (1.01–1.05) <0.01 1.02 (0.99–1.05) ns
V50 EIM (%) 1.01 (1.00–1.02) <0.01 1.00 (0.99–1.01) ns 1.00 (0.99–1.01) ns 1.01 (1.00–1.02) ns 1.02 (1.01–1.03) <0.01
V60 EIM (%) 1.01 (0.99–1.02) ns 1.01 (0.99–1.02) ns 1.00 (0.99–1.02) ns 1.01 (1.00–1.02) 0.048 1.03 (1.01–1.04) <0.01
Mean dose cervical oesophagus (Gy) 1.04 (1.02–1.05) <0.01 1.01 (0.99–1.03) ns 1.02 (1.00–1.04) 0.03 1.03 (1.01–1.05) <0.01 1.02 (0.99–1.05) ns
Mean dose base of tongue (Gy) 1.06 (1.04–1.08) <0.01 1.02 (0.99–1.03) ns 1.04 (1.02–1.06) <0.01 1.04 (1.02–1.07) <0.01 1.00 (0.98–1.02) ns
Mean dose supraglottic larynx (Gy) 1.05 (1.02–1.07) <0.01 1.08 (1.04–1.13) <0.01 1.05 (1.02–1.08) <0.01 1.05 (1.02–1.09) <0.01 1.09 (1.02–1.16) <0.01
Mean dose glottic larynx (Gy) 1.01 (0.99–1.02) ns 1.02 (1.00–1.05) 0.045 1.01 (0.99–1.03) ns 1.01 (0.99–1.03) ns 1.04 (1.00–1.08) 0.04
Mean dose parotid glands (Gy) 1.05 (1.04–1.07) <0.01 1.02 (1.00–1.04) 0.027 1.03 (1.02–1.05) <0.01 1.05 (1.03–1.07) <0.01 1.02 (0.99–1.04) ns
Mean dose submandibular glands (Gy) 1.05 (1.03–1.07) <0.01 1.03 (1.01–1.05) <0.01 1.04 (1.02–1.06) <0.01 1.05 (1.03–1.07) <0.01 1.01 (0.99–1.03) ns
Sex (male vs. female) 0.86 (0.50–1.46) ns 1.26 (0.59–2.71) ns 1.08 (0.50–2.35) ns 0.47 (0.19–1.19) ns 0.52 (0.15–1.81) ns
Age (18–65 vs.>65 years) 0.68 (0.41–1.13) ns 1.30 (0.65–2.59) ns 1.68 (0.86–3.29) ns 1.03 (0.54–1.98) ns 2.14 (0.86–5.33) ns
T-stage (T0–2 vs. T3–4) 2.98 (1.82–4.87) <0.01 0.68 (0.30–1.57) ns 1.14 (0.56–2.35) ns 1.36 (0.67–2.75) ns 1.14 (0.44–2.94) ns
N-stage (N0 vs. N+) 4.56 (2.72–7.64) <0.01 0.88 (0.43–1.82) ns 2.25 (1.14–4.44) 0.019 2.38 (1.23–4.60) 0.01 0.45 (0.16–1.27) ns
Tumour site (others vs. oro-/nasopharynx) 4.61 (2.77–7.67) <0.01 1.43 (0.67–3.02) ns 2.92 (1.46–5.86) <0.01 3.19 (1.57–6.49) <0.01 0.63 (0.21–1.95) ns
Concomitant chemotherapy (no vs. yes) 3.94 (2.28–6.83) <0.01 1.42 (0.60–3.35) ns 2.79 (1.29–6.06) <0.01 2.20 (0.96–5.00) ns 0.22 (0.03–1.65) ns
Radiation technique (3D-CRT vs. IMRT) 1.57 (0.97–2.54) ns 0.31 (0.12–0.76) 0.011 0.60 (0.28–1.29) ns 0.86 (0.43–1.76) ns 0.30 (0.09–1.03) ns
Accelerated radiotherapy (no vs. yes) 0.79 (0.49–1.27) ns 1.11 (0.55–2.27) ns 0.70 (0.36–1.38) ns 1.01 (0.52–1.97) ns 0.97 (0.38–2.44) ns
Bilateral neck irradiation (no vs. yes) 5.96 (2.87–12.3) <0.01 3.46 (1.39–8.63) <0.01 3.38 (1.36–8.37) <0.01 5.11 (2.07–12.61) <0.01 1.96 (0.64–6.02) ns
Baseline swallowing dysfunction (RTOG grade 0 vs. grade 1) 3.27 (1.76–6.06) <0.01 Not applicable Not applicable Not applicable Not applicable
Swallowing complaints (no vs. mild) Not applicable 0.77 (0.33–1.77) ns 1.61 (0.73–3.55) ns 2.45 (1.24–4.82) <0.01 4.22 (1.62–10.99) <0.01
Abbreviations: PCM = pharyngeal constrictor muscle, EIM = oesophagus inlet muscle.
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Table 3
Results of the multivariate analysis of the primary and secondary endpoints.
Variable b OR 95% Cl p-value AUC 95% CI
Model for Grade 2–4 RTOG late swallowing dysfunction 0.80 0.75–0.85
Mean dose superior PCM (Gy) 0.057 1.06 1.04–1.08 <0.01
Mean dose supraglottic larynx (Gy) 0.037 1.04 1.01–1.06 <0.01
Model for Q35: Problems with swallowing liquids (moderate to severe) 0.75 0.68–0.83
Mean dose supraglottic larynx (Gy) 0.074 1.08 1.03–1.12 <0.01
Radiation technique (3D-CRT vs. IMRT) 1.209 0.30 0.12–0.76 0.011
Model for Q36: Problems with swallowing soft food (moderate to severe)
Mean dose middle PCM 0.061 1.06 1.03–1.10 <0.01 0.79 0.72–0.86
Age (18–65 vs. >65 years) 1.203 3.33 1.50–7.41 <0.01
Tumour site (Other sites vs. oro-/nasopharynx) 1.122 3.07 1.37–6.90 <0.01
Radiation technique (3D-CRT vs. IMRT) -0.912 0.40 0.17–0.93 0.032
Model for Q37: Problems with swallowing solid food (moderate to severe) 0.77 0.70–0.84
Mean dose superior PCM (Gy) 0.049 1.05 1.03–1.07 <0.01
Mean dose supraglottic larynx (Gy) 0.048 1.05 1.01–1.09 <0.01
Age (18–65 vs. > 65 years) 0.795 2.21 1.02–4.79 0.044
Model for Q38: Choking when swallowing (moderate to severe) 0.77 0.67–0.86
V60 oesophageal inlet muscle (%) 0.020 1.02 1.01–1.03 <0.01
Mean dose supraglottic larynx (Gy) 0.066 1.07 1.00–1.36 0.042
Fig. 1. Normal tissue complication probability curves for SWALM6 for each 10 Gy
increase in dose to the supraglottic larynx. Abbreviations: NTCP = normal tissue
complication probability, PCM = pharyngeal constrictor muscle, MD SGL = mean
dose supraglottic larynx.
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the formula:
NCTP ¼ ð1þ esÞ1; in which
S = 5.98 + (mean dose supraglottic larynx  0.074) + (radiation
technique  1.209).
The NTCP-curves for the different categories are depicted in
Fig. 2a, and the nomogram for problems with swallowing liquids
in Appendix B1.Problems with swallowing soft food
For problems with swallowing soft food, the model was most
optimal with four variables, including the mean dose to the middle
PCM, age (18–65 versus >65 years), tumour site (oropharynx/naso-
pharynx versus other sites), and radiation technique (3D-CRT
versus IMRT). The AUC for this 4-factor model was 0.79 (95% CI
0.72–0.86). The OR’s for each of the 4 selected variables are shown
in Table 3. The NTCP-value for the individual patient can be calcu-
lated using the formula:
NCTP ¼ ð1þ esÞ1; in which
S = 5.83 + (mean dose middle PCM  0.061) + (age  1.203) +
(tumour site  1.122) + (radiation technique  0.912).
The NTCP-curves for the different categories are depicted in
Fig. 2b, and the nomogram for problems with swallowing soft food
can be found in Appendix B2.Problems with swallowing solid food
For problems with swallowing solid food, the model was most
optimal when consisting of three variables, including the mean
dose to the superior PCM, the mean dose to the supraglottic larynx,
and age (18–65 versus >65 years) . The AUC for this 3-factor model
was 0.78 (95% CI 0.71–0.85). The OR’s for each of the 3 selected
variables are shown in Table 3. The NTCP-value for the individual
patient can be calculated using the formula:
NCTP ¼ ð1þ esÞ1; in which
S = 6.89 + (mean dose superior PCM  0.049) + (mean dose supra-
glottic larynx  0.048) + (age  0.795).
The NTCP-curves for the different categories are depicted in
Fig. 2c, and the nomogram for problems with swallowing solid
food in Appendix B3.Choking when swallowing
For choking when swallowing, the model was most optimal
with 2 variables, including the V60 of the EIM and the mean dose
to the supraglottic larynx. The AUC for this 2-factor model was 0.77
(95% CI 0.67–0.86). The OR’s for each of the 2 selected variables are
shown in Table 3. The NTCP-value for the individual patient can be
calculated using the formula:
NCTP ¼ ð1þ esÞ1; in which
Fig. 2. Normal tissue complication probability curves for patient rated swallowing dysfunction: (a). Liquids (b). Soft food (c). Solid food (d). Choking. Abbreviations:
NTCP = normal tissue complication probability, PCM = pharyngeal constrictor muscle, NPC = nasopharyngeal cancer, OPC = oropharyngeal cancer, MD SGL = mean dose
supraglottic larynx, EIM = oesophagus inlet muscle.
112 Predictive modelling swallowing dysfunctionS = 7.07 + (V60 EIM  0.020) + (mean dose supraglottic larynx 
0.066)
The NTCP-curves for the different categories for choking when
swallowing are depicted in Fig. 2d and the nomogram in Appendix
B4.Discussion
The primary objective of the current study was to develop a pre-
dictive model for grade 2–4 swallowing dysfunction according to
the RTOG/EORTC Late Radiation Morbidity Scoring Criteria as as-
sessed 6 months after completion of (CH) RT (SWALM6). The anal-
ysis showed that the combination of two factors, including the
mean dose to the superior pharyngeal constrictor muscle and themean dose to the supraglottic larynx provided a predictive model
with good performance.
To our knowledge, this is the ﬁrst prospectively designed cohort
study that speciﬁcally aimed at developing a predictive model for
radiation induced swallowing dysfunction (RISD) in HNC patients
treated with primary curatively intended (CH) RT. The prospective
design of this study had several advantages. First, by assessing
swallowing dysfunction at baseline, we could exclude patients
who already had grade 2–4 swallowing dysfunction prior to (CH)
RT. As we were primarily interested in radiation-induced swallow-
ing dysfunction, we decided to exclude these patients as their swal-
lowing dysfunction was most likely caused by local tumour
extension. As a consequence, the predictive model presented in this
paper is only applicable for those patients without grade 2–4 swal-
lowing dysfunction prior to treatment. Second, the prospective
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tudinal rather than a cross-sectional design [2,13,14,19,21,30–32]
which is a prerequisite to assess possible dose–volume effect rela-
tionships in potential swallowing organs at risk (SWOARs).
One of the shortcomings of studies reporting on the relationship
between dose-volume parameters and RISD is that only univariate
relationships were estimated [2,13,17,18,30–34]. In the present
study, we used a multivariate logistic regression analysis with
bootstrapping as described by El Naqa et al. [29]. As pointed out
by these authors, prediction of endpoints like SWALM6 can be im-
proved by mixing clinical and dose–volume factors, while boot-
strap-based variable selection analysis increases the reliability of
the predictive models. Indeed, our results showed higher perfor-
mance of the multivariate model compared to the univariate rela-
tionships between dose–volume parameters and SWALM6.
Moreover, the multivariate approach and the nomograms allow
for an integration of different prognostic variables in estimating
the risk on SWALM6 in individual patients. In this regard, it should
be stressed that dose–effect relationships for this endpoint should
be described by multiple NTCP-curves rather than by one single
NTCP-curve.
In a previous study, we reported on a predictive model on
SWALM6 in which dose-volume parameters were not taken into
account [20]. In that study, T3–T4 stage, bilateral neck irradiation,
weight loss prior to radiotherapy, primary tumour site in the oro-
pharynx or nasopharynx, concurrent chemoradiation and acceler-
ated radiotherapy were identiﬁed as risk factors for the same
endpoint as used in the current analysis. The majority of these
prognostic factors, such as T-stage (larger volumes), bilateral neck
irradiation and primary tumour site signiﬁcantly correlate with the
mean dose in the PCM superior and supraglottic larynx. The fact
that the addition of concurrent chemotherapy to radiation and
accelerated radiotherapy were not selected by the multivariate
analysis as prognostic factors in the current study, suggests that
the higher incidence of SWALM6 with these treatment regimens
are mainly explained by larger tumour volumes with subsequent
larger irradiated volumes of the SWOARs, rather than the treat-
ment regimens itself.
The present study shows a difference in the predictive models
found for the different patient-rated swallowing problems regard-
ing food consistencies. Moreover, the results suggest a relationship
between food consistency and the anatomical localisation related
to that speciﬁc problem. At ﬁrst sight, this may seem rather confus-
ing. However, these different results can be well explained when
taking into account the normal swallowing process, which involves
multiple muscles and structures. When viscosity increases the
pressure generated by the swallow mechanism needs to be in-
creased as well [35]. This pressure is built up from cranial to cau-
dal, meaning the higher the food viscosity, the more cranial the
pressure build-up needs to be initiated. This may very well explain
the superior PCM to be most important for solid food. Laryngeal
elevation and cricopharyngeal opening is necessary for pharyngeal
clearance. Lack of pharyngeal clearance may lead to patient’s self-
restriction in the amount and viscosity of food taken [36,37]. In
combination with inadequate airway closure at the supraglottic
larynx, this could lead to aspiration [38]. These ﬁndings are in
agreement with the ﬁndings of the present study, in which the
SWOARs identiﬁed for aspiration were the supraglottic larynx
and EIM.
An important ﬁnding of the present study is the selection of the
radiation technique IMRT as a positive prognostic factor for pa-
tient-rated problems with swallowing liquids and soft food. In an
earlier study, Vergeer et al. [8] found lower scores for patient-rated
swallowing dysfunction as assessed by the EORTC QLQ-H&N35,
when treated with IMRT compared with standard 3D-CRT, proba-
bly due to lower doses in the normal tissues. One might expect thatthe mean dose in the SWOARs is lower with IMRT compared to 3D-
CRT, however this was not the case in our cohort (data not shown).
In fact, the mean total doses to all SWOARs did not differ between
the 3D-CRT and IMRT patients (data not shown). However, it
should be taken into account that with the IMRT SIB technique,
the prescribed fraction dose to the elective regions was 1.55 Gy gi-
ven in 35 fractions in 6–7 weeks as compared to 2 Gy per fraction
up to a total dose of 46 Gy in 4–5 weeks when 3D-CRT was used.
From a radiobiological point of view, the lower dose per fraction
and possibly the prolongation of the overall treatment time of
the elective dose may very well explain the lower incidence of pa-
tient-rated swallowing dysfunction 6 months after completion of
(CH) RT. Moreover, these results are in line with those reported
by Bhide et al. [39] in relation to acute toxicity.
A number of other authors reported on the relationship be-
tween patient-rated swallowing dysfunction after (CH) RT and
dose distributions in SWOARs [2,19,21,32–34]. In summary, the
dose distributions in different parts of the PCM, dose to the (supra-
glottic) larynx, the pre-treatment swallowing problems and use of
brachytherapy were found to be associated with different kinds of
patient-rated swallowing dysfunction, which is in line with the
ﬁndings of the present study.
In conclusion, we developed predictive models for physician-
rated and patient-rated swallowing dysfunction in HNC patients
treated with (CH) RT, using multivariate bootstrap logistic regres-
sion analysis. The results of our study illustrate that these different
endpoints cannot be predicted with univariate relationships be-
tween dose distribution in a single SWOAR and these endpoints,
but that separate NTCP models are needed for different endpoints,
and that factors other than DVH parameters are important as well.
These results are currently being validated in a subsequent cohort
study at our institutions.
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